Protocol Ledger

NCT05557942 · Phase III · TERMINATED

Inhaled Imatinib Pulmonary Arterial Hypertension Clinical Trial - Follow Up Long Term Extension (IMPAHCT-FUL)

Interventional Phase III clinical trial protocol NCT05557942 sponsored by Aerovate Therapeutics in Cardiovascular and Thrombosis, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2022-11-02 Enrollment: 186 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05557942
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)186 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05557942
Protocol FieldVerified Registry Value
NCT IdentifierNCT05557942
Consolidated Lead SponsorAerovate Therapeutics
Therapeutic Condition CohortCardiovascular and Thrombosis
Clinical Trial PhasePhase III
Overall Recruitment StatusTERMINATED
Registered Enrollment186 participants (ACTUAL)
Registered Start Date2022-11-02
WhyStopped ClassificationUnspecified

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Cardiovascular and Thrombosis Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI